- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04954547
The Effect of Activities-based Subsidy on Body Fat Loss
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study, which spans 24 weeks (12 treatment, 12 post-treatment), aims to compare the effectiveness of 2 financial incentive structures - a conditional subsidy versus a goal reward - on fat loss. 600 overweight but otherwise healthy female Singaporeans or Permanent Residents will be recruited via 2 recruitment phases, 2 months apart from each other. Participants will be given an individual-tailored percentage body fat (PBF) goal and assigned to one of three interventions:
- Subsidy treatment group (STG) - Participants will be awarded $X for reaching the PBF goal at the end of 12 weeks. Regardless of goal attainment, participants will also be reimbursed 50% of approved health-improving expenses up to a cap of $Y in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts to the program website and simply be reimbursed at the end of the experiment. To prevent cheating, all receipts must bear the participants' full name or be justifiably traceable to them. When submitting the receipt to the program website, they must also specify the purpose of the expense - this serves as a psychological reminder to utilize the expense more meaningfully, while allowing us to discern better to approve or reject the reimbursement claim.
- Cash treatment group (CTG). Participants will be awarded $(X+Y) for reaching the PBF goal at the end of 12 weeks.
- Control. Other than the participation fees, no additional incentives will be provided.
All participants will be given an individual-tailored 12-week PBF goal. The formula for this goal will be set following the approval of the IRB, in consultation with medical and fitness professionals (including certified doctors and fitness trainers) to ensure that it is safe, challenging, and achievable. The base formula, which assumes a 5% weight loss as is often defined to be the medically significant level, is:
(P*W-x*5%*W)/(95%*W)
where P is PBF at baseline (week 1), W is body mass in kg at baseline, P×W is their body fat mass at baseline, and x, ranging between 0% and 100%, is the parameter that is set in consultation with professionals. At 100%, it implies that all 5% in weight loss is from fat, vice versa.
Because P and W differ between most persons, our formula tailors a different goal to each research subject. Our formula is meant to be flexible toward each participant's baseline weight and body fat percent. Leveraging the 5% weight loss target, the investigators determined the expected percentage of this weight that is lost as fat, knowing that weight loss includes not only fat loss but also other components such as water loss. In previous studies, for 1 kg loss in weight, on average, 78.8% came from body fat. Hence, the investigators have targeted 80% of weight loss from our participants to come from body fat.
To examine changes in health, objective measurements will be made during scheduled participant visits on Weeks 1, 12, and 24. Measures include height, weight, waist circumference, and PBF. Each participant will also be given a free digital scale for personal use from home. Their weight and PBF data from the scale will be synchronized to a mobile application, which we will retrieve with the participant's consent, to examine changes throughout the study's duration.
There are a total of 3 scheduled visits. The first in Week 1 allows us to determine the baseline measures. The second visit in Week 12 marks the end of the treatment and allows us to investigate treatment effects. The last visit in Week 24 checks for post-treatment effects. During all 3 visits, the participants will also complete a Health Risk Assessment Survey. This survey should take no longer than 10 minutes to complete, and the research team will be physically present to assist them with it if so required.
Due to the uncertainty of the pandemic, the investigators may hold the second and/or the third research visits virtually (or at least provide an online option) to avoid large gatherings if necessary. For each virtual research visit, the research team will contact the participants through a video call, during which they will step on the weighing scales and show the readings to the team. If a research visit is held online, the participation fee/rewards will be sent electronically. The research team will still hold physical meetings for those who experience technical difficulties.
To let participants track their PBF progress, every participant would be given a digital scale for their keeping even after the research has concluded. The scale, named 'Lite Mould Body Composition Smart Scale', priced at US$13 (before shipping) is commercially available and will be supplied by the manufacturer 'Yolanda'. It comes with a free mobile application to let them track their progress. The app is publicly available on the Apple and Google Play stores for free under the name 'Feelfit' by Shenzhen QingNiu Software Co. Ltd. Referring to the Health Products Act (HPA), this scale would not be defined as a "medical device". The digital scale serves simply, as would a conventional scale, to inform the user on some bodily metric. It does not attempt to make any medical judgment or recommendation for the user. The research team has done testing on the digital scale and is satisfied with the precision of the device. The participants are expected to weigh-in on the scales weekly from home at their convenience. In the middle of each of the 12 weeks (e.g. Wednesday or Thursday), an automated email will be sent to the participants reminding them to do so by the end of the week (Sunday). Non-compliance will not be penalized, but participants are strongly encouraged to weigh-in. The following is the complete list of data that the participants will have access to from the scale's mobile application. The researchers, with the participants' consent, will also retrieve this data for analysis: 1. Basal metabolism rate; 2. BMI; 3. Bone mass; 4. Metabolic age; 5. Muscle mass; 6. PBF; 7. Skeletal muscle weight ratio; 8. Subcutaneous fat; 9. Total body water; 10. Visceral fat; 11. Weight
The study will be split into two waves of 300 participants. The investigators will start the first wave when they successfully recruit 300 eligible participants in the first recruitment phase and the second wave with another 300 eligible participants in the second recruitment phase.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ta-Cheng Huang, PhD
- Phone Number: +6566012086
- Email: tchuang@nus.edu.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- National University of Singapore
-
Contact:
- Ta-Cheng Huang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Singaporeans or Permanent Residents
- Female
- Overweight (BMI: 23 to 27.5)
- Participants need to own a smartphone or tablet
- Must be able to commit to a 24-week research program focused on improving health
- Own a smartphone or tablet
Exclusion Criteria:
- Chronically diseased (e.g. hypertension, hyperglycemia, hyperlipidemia), or is suffering or suffered from medical conditions (e.g. stroke, heart attack).
- Currently pregnant or breastfeeding or intending to become pregnant over the next year
- Currently participating in any other research program focused on physical activity or weight loss
- Currently taking any prescribed medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Subsidy Arm
Participants in the arm will receive $$50 if they reach the PBF goal and will be subsidized on approved health-improving expenses.
|
Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks.
Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks.
The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).
|
|
Experimental: Cash Arm
Participants in the arm will receive S$350 if they reach the PBF goal.
|
Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
|
|
No Intervention: Control
Other than the participation fees, no additional incentives will be provided.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Whether reaching the prescribed PBF goal
Time Frame: At the end of the 12 weeks
|
This is binary variable, which is 1 if the participant reaches the prescribed PBF goal, and 0 otherwise
|
At the end of the 12 weeks
|
|
Whether maintaining what has achieved in the post-treatment period
Time Frame: At the end of the 24 weeks
|
This is binary variable, which is 1 if the participant loses more fat in the post-treatment period than in the intervention period, and 0 otherwise.
|
At the end of the 24 weeks
|
|
Achievement Percentage
Time Frame: At the end of the 24 weeks
|
A percentage of the change in PBF from the predetermined change in PBF
|
At the end of the 24 weeks
|
|
Weekly Achievement Percentage
Time Frame: Through study completion (24 weeks)
|
A percentage of the change in PBF from the predetermined change in PBF
|
Through study completion (24 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Noah Lim, PhD, The Global Asia Institute, The National University of Singapore
- Principal Investigator: Ta-Cheng Huang, PhD, The Global Asia Institute, The National University of Singapore
- Principal Investigator: Andrea Chung, PhD, Booz Allen Hamilton
- Principal Investigator: Kegon Tan, PhD, University of Rochester
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NUS-IRB-2020-643
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
National University Health System, SingaporeActive, not recruitingObesity | Overweight and/or Obesity | Overweight or Obese Adults | Overweight , ObesitySingapore
-
Carmen Lucas AbellánUniversidad Católica San Antonio de MurciaCompletedOverweight/Obesity | Overweight or Obese | Overweight or Obese Adults | Obesity and Overweight | Obese SubjectsSpain
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Children's Hospital Los AngelesEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
Empros Pharma ABNot yet recruitingOverweight or Obese | Obesity and Overweight
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight, Childhood | Overweight, InfantFrance
-
Medialis Ltd.RecruitingObesity & Overweight | Overweight (BMI > 25)United Kingdom
-
Federal University of Health Science of Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Active, not recruitingObesity & Overweight | Overweight (BMI > 25)Brazil
-
National Taiwan University HospitalCompleted
Clinical Trials on Subsidy Treatment
-
Cornell UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedObesity | Diet | Health Behavior | Food LabelingUnited States
-
University of California, San FranciscoNational Institute of Mental Health (NIMH); Muhimbili University of Health...Not yet recruiting
-
The Aquaya InstituteUnited States Agency for International Development (USAID); TetratechCompleted
-
Nicholas RahimCompletedMaternal and Child Health OutcomesMalawi
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Kenya Medical Research InstituteCompletedHepatitis B | Measles | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type bKenya
-
Columbia UniversityUniversity of California, Santa Barbara; Kintampo Health Research Centre, GhanaCompleted
-
University of CalgaryCanadian Institutes of Health Research (CIHR); British Columbia Farmers' Market... and other collaboratorsCompleted
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Moi University; Clinton Health Access Initiative, NigeriaCompletedMalaria | Febrile IllnessKenya
-
Harvard School of Public Health (HSPH)Fogarty International Center of the National Institute of HealthRecruitingHeat Stress | Heat Exposure | Heat Effect | Hot Weather; Adverse Effect | Heat Stroke, Heat Exhaustion | Heat StrainUnited States
-
Turtle Health, Inc.WithdrawnFertility RiskUnited States